KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)

Historical Holders from Q4 2016 to Q3 2025

Symbol
KALV on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
50M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
58.6M
Holdings value
$714M
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
143
Number of buys
77
Number of sells
-62
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 9.9% $63.7M 4.94M TANG CAPITAL MANAGEMENT, LLC 31 Mar 2025
Frazier Life Sciences Public Fund, L.P. 6.9% +42% $42.2M $13M 3.47M +44.4% Frazier Life Sciences Public Fund, L.P. 01 Nov 2025
Capital World Investors 6.4% $40.9M 3.18M Capital World Investors 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 5% $30.8M 2.53M Millennium Management LLC 04 Nov 2025
Vestal Point Capital, LP 1.5% $9.14M 750K Vestal Point Capital, LP 30 Sep 2025

Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 58.6M $714M +$51.9M $12.18 143
2025 Q2 54.4M $616M -$5.35M $11.31 138
2025 Q1 54.9M $634M +$5.36M $11.54 127
2024 Q4 55.2M $467M +$30.4M $8.47 129
2024 Q3 48.4M $561M +$549K $11.58 120
2024 Q2 48.2M $568M +$14.3M $11.78 118
2024 Q1 47M $557M +$118M $11.86 128
2023 Q4 37M $453M +$5.79M $12.25 92
2023 Q3 36.3M $349M +$17.9M $9.63 101
2023 Q2 34.5M $310M +$8.86M $9.00 93
2023 Q1 33.7M $265M -$7.24M $7.86 87
2022 Q4 33.8M $229M +$23.5M $6.76 88
2022 Q3 25.6M $372M +$16.6M $14.51 88
2022 Q2 24.3M $239M -$18.2M $9.84 84
2022 Q1 24M $353M -$11.7M $14.74 84
2021 Q4 23.8M $315M -$24.2M $13.23 93
2021 Q3 23.4M $408M -$21.5M $17.45 101
2021 Q2 24.3M $583M +$12.1M $23.96 108
2021 Q1 23.5M $604M +$241M $25.69 115
2020 Q4 14.7M $278M +$4.36M $18.99 79
2020 Q3 16.2M $204M +$2.82M $12.59 61
2020 Q2 16M $194M +$9.42M $12.10 72
2020 Q1 15.7M $120M +$17.2M $7.65 68
2019 Q4 13.7M $244M +$13.4M $17.81 73
2019 Q3 13.2M $153M -$34M $11.60 75
2019 Q2 14.8M $328M +$6.28M $22.15 74
2019 Q1 13.9M $398M +$23.9M $28.62 67
2018 Q4 13M $256M +$7.7M $19.75 56
2018 Q3 12.3M $272M +$113M $22.11 46
2018 Q2 6.32M $51.3M -$1.6M $8.12 24
2018 Q1 6.5M $61.6M +$134K $9.48 23
2017 Q4 6.48M $63.2M -$3M $9.75 23
2017 Q3 7.72M $52.2M +$2.31M $6.73 15
2017 Q2 7.37M $54.1M -$1.77M $7.36 17
2017 Q1 7.59M $59.2M +$2.02M $7.81 18
2016 Q4 7.33M $51.5M +$47M $7.07 18